Alberto Corriero, Mariateresa Giglio, Rossana Soloperto, Francesco Inchingolo, Giustino Varrassi, Filomena Puntillo
{"title":"Microbial Symphony: Exploring the Role of the Gut in Osteoarthritis-Related Pain. A Narrative Review","authors":"Alberto Corriero, Mariateresa Giglio, Rossana Soloperto, Francesco Inchingolo, Giustino Varrassi, Filomena Puntillo","doi":"10.1007/s40122-024-00602-9","DOIUrl":null,"url":null,"abstract":"<p>One of the most common musculoskeletal disorders, osteoarthritis (OA), causes worldwide disability, morbidity, and poor quality of life by degenerating articular cartilage, modifying subchondral bone, and inflaming synovial membranes. OA pathogenesis pathways must be understood to generate new preventative and disease-modifying therapies. In recent years, it has been acknowledged that gut microbiota (GM) can significantly contribute to the development of OA. Dysbiosis of GM can disrupt the “symphony” between the host and the GM, leading to a host immunological response that activates the “gut–joint” axis, ultimately worsening OA. This narrative review summarizes research supporting the “gut–joint axis” hypothesis, focusing on the interactions between GM and the immune system in its two main components, innate and adaptive immunity. Furthermore, the pathophysiological sequence of events that link GM imbalance to OA and OA-related pain is broken down and further investigated. We also suggest that diet and prebiotics, probiotics, nutraceuticals, exercise, and fecal microbiota transplantation could improve OA management and represent a new potential therapeutic tool in the light of the scarce panorama of disease-modifying osteoarthritis drugs (DMOADs). Future research is needed to elucidate these complex interactions, prioritizing how a particular change in GM, i.e., a rise or a drop of a specific bacterial strain, correlates with a certain OA subset to pinpoint the associated signaling pathway that leads to OA.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":"52 1","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40122-024-00602-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
One of the most common musculoskeletal disorders, osteoarthritis (OA), causes worldwide disability, morbidity, and poor quality of life by degenerating articular cartilage, modifying subchondral bone, and inflaming synovial membranes. OA pathogenesis pathways must be understood to generate new preventative and disease-modifying therapies. In recent years, it has been acknowledged that gut microbiota (GM) can significantly contribute to the development of OA. Dysbiosis of GM can disrupt the “symphony” between the host and the GM, leading to a host immunological response that activates the “gut–joint” axis, ultimately worsening OA. This narrative review summarizes research supporting the “gut–joint axis” hypothesis, focusing on the interactions between GM and the immune system in its two main components, innate and adaptive immunity. Furthermore, the pathophysiological sequence of events that link GM imbalance to OA and OA-related pain is broken down and further investigated. We also suggest that diet and prebiotics, probiotics, nutraceuticals, exercise, and fecal microbiota transplantation could improve OA management and represent a new potential therapeutic tool in the light of the scarce panorama of disease-modifying osteoarthritis drugs (DMOADs). Future research is needed to elucidate these complex interactions, prioritizing how a particular change in GM, i.e., a rise or a drop of a specific bacterial strain, correlates with a certain OA subset to pinpoint the associated signaling pathway that leads to OA.
骨关节炎(OA)是最常见的肌肉骨骼疾病之一,它通过使关节软骨退化、软骨下骨改变和滑膜发炎,导致全球范围内的残疾、发病率和生活质量下降。必须了解 OA 的发病机制,才能开发出新的预防和改善疾病的疗法。近年来,人们已认识到肠道微生物群(GM)对 OA 的发病有重要影响。肠道微生物菌群失调会破坏宿主与肠道微生物菌群之间的 "交响乐",导致宿主免疫反应,激活 "肠道-关节 "轴,最终加重 OA。本综述总结了支持 "肠道-关节轴 "假说的研究,重点关注转基因与免疫系统之间的相互作用,包括先天性免疫和适应性免疫两个主要组成部分。此外,我们还对将全球机制失衡与 OA 和 OA 相关疼痛联系起来的病理生理学事件序列进行了细分和进一步研究。我们还建议,饮食和益生元、益生菌、营养保健品、运动和粪便微生物群移植可以改善 OA 的管理,并在改变疾病的骨关节炎药物(DMOADs)稀缺的情况下成为一种新的潜在治疗工具。未来的研究需要阐明这些复杂的相互作用,优先考虑基因组中的特定变化(即特定细菌菌株的增加或减少)如何与特定的 OA 亚群相关联,以确定导致 OA 的相关信号通路。
期刊介绍:
Pain and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of pain therapies and pain-related devices. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, acute pain, cancer pain, chronic pain, headache and migraine, neuropathic pain, opioids, palliative care and pain ethics, peri- and post-operative pain as well as rheumatic pain and fibromyalgia.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, trial protocols, short communications such as commentaries and editorials, and letters. The journal is read by a global audience and receives submissions from around the world. Pain and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.